QZQianqian Zhu

Qianqian Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qianqian Zhu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Jiaying Lin

    Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People’s Hospital, Shanghai, China

    11 shared publications
  • Bian Wang

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    9 shared publications
  • Haiyan Guo

    Shanghai Jiao Tong University School of Medicine, Shanghai Ninth People’s Hospital, Shanghai, China

    8 shared publications
  • Qifeng Lyu

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute, Shanghai, China

    5 shared publications
  • Mingru Yin

    Department of Assisted Reproduction Shanghai Ninth People's Hospital, Jiao Tong University School of Medicine Shanghai China

    4 shared publications
  • Qiuju Chen

    Department of Assisted Reproduction, Shanghai Ninth People’s Hospital Affiliated to JiaoTong University School of Medicine , Shanghai

    4 shared publications

Latest Publications

  • Open Access

    Correction: A prospective cohort study on progestin-primed ovarian stimulation vs. GnRH antagonist in IVF-ICSI cycles: effects on clinical pregnancy and neonatal outcomes

    by Chuning Yang, Qiuju Chen, Xi Shen, Haiyan Guo, Jiaying Lin, Xuefeng Lu, Xiaowei Wen, Qianqian Zhu, Weiran Chai

  • Association of hepatitis B virus infection with oocyte quality, embryo development, and ART outcomes in couples with a freeze-all strategy at a single center

    by Jiaying Lin, Qiuju Chen, Yining He, Mingru Yin, Qianqian Zhu

    STUDY QUESTION: Does female or male hepatitis B virus (HBV) infection affect the oocyte and embryo quality, pregnancy outcomes, and neonatal outcomes in infertile couples undergoing ART treatment? SUMMARY ANSWER: The female or male HBV infection did not have a statistically significant negative impact on the development of oocytes and embryos, pregnancy outcomes, or neonatal outcomes of ART. WHAT IS KNOWN ALREADY: Only few studies assessing the effects of HBV infection on the reproductive outcomes among infertile population have been conducted with inconsistent results. There is limited research that focuses on the oocyte and embryo development of HBV-infected females and males. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study was performed among infertile couples undergoing the first frozen embryo transfer (FET) after the first ovarian stimulation with a freeze-all strategy during the period from 1 January 2011 to 31 March 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 24 836 infertile couples, including 133 couples with female HBV-positive and male HBV-negative, 1471 couples with female HBV-negative and male HBV-positive, and 23 232 couples with both female and male HBV-negative underwent their first FET after the first ovarian stimulation with a freeze-all strategy. Propensity score matching (PSM) was used to balance the baseline parameters between the groups. MAIN RESULTS AND THE ROLE OF CHANCE: After PSM, no statistically significant differences were observed regarding the comparison in the number of oocytes retrieved, MII oocytes, 1-2-3 PN-fertilized oocytes, 2PN-fertilized oocytes, embryo cleavages, available embryos, top-quality embryos, and available blastocysts between comparison groups (group with female HBV-positive and male HBV-negative and group with female HBV-negative and male HBV-positive) and the reference group. Consistently, the differences in the mature oocyte rate, fertilization rate, cleavage rate, as well as top-quality embryo rate and available embryo rate between comparison groups and the reference group were not statistically significant. The clinical pregnancy rate and the live birth rate showed a decreasing trend for couples with female HBV infection compared with the uninfected couples, although this did not reach statistical significance (clinical pregnancy: adjusted odds ratio, 0.69 [95% CI: 0.45–1.05] and live birth: 0.64 [0.41–1.00]). Couples with female HBV infection and couples with male HBV infection were not associated with increased risk of adverse neonatal outcomes including preterm birth, low birth weight, high birth weight, small for gestational age, and large for gestational age. LIMITATIONS, REASONS FOR CAUTION: This was a retrospective cohort study in a single center, which limited the generalization of our results. WIDER IMPLICATIONS OF THE FINDINGS: HBV infection was not statistically significantly associated with development of oocyte and embryo quality, pregnancy outcomes, and neonatal outcomes. These findings indicate infertile women or male with HBV infection should not be prevented from seeking ART due to concerns about negative effects. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the National Natural Science Foundation of China (grant nos. 82273634, 81903324), the interdisciplinary program of Shanghai Jiao Tong University (YG2019QNA19), and the second round of Promoting clinical skills and clinical innovation in municipal hospitals New three-year Action Plan “Research physicians innovation and transformation ability Strength training program” (SHDC2023CRS031). There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.


  • Open Access

    Impact of letrozole co-treatment in an antagonist protocol for IVF/ICSI: a retrospective study

    by Jing Lin, Fenglu Wu, Bian Wang, Qianqian Zhu, Jiaying Lin

    The present study aimed to investigate the impact of combined use of letrozole in an antagonist protocol during IVF on live birth outcomes and to assess the safety of letrozole in terms of maternal and neonatal complications. This retrospective cohort study included women undergoing IVF/ICSI and fresh embryo transfer (ET) treatment with and without letrozole co-treatment from 2007 to 2021 at Shanghai Ninth People’s Hospital (Shanghai, China). The primary outcome was the live birth rate, while the incidences of maternal and neonatal complications were secondary outcomes. Logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the analyzed outcomes. Sensitivity analysis was performed using a propensity score-based patient-matching (PSM) model, an inverse probability weighting (IPW) model, logistic regression models with women undergoing their first IVF-ET cycle, and subgroup analysis. Of the 4780 women enrolled in the study, 3887 underwent an antagonist protocol for ovarian stimulation, while 893 received letrozole co-treatment. In this cohort, letrozole co-treatment demonstrated comparable live birth rates to the use of antagonist protocol alone (logistic regression: aOR, 0.88; 95% CI, 0.71–1.08; PSM: aOR, 0.97; 95% CI, 0.77–1.22; IPW: aOR, 0.88; 95% CI, 0.71–1.10). Notably, individuals with a body mass index (BMI) exceeding 24 and those with high ovarian response experienced higher live birth rates under the letrozole co-treatment regimen (BMI ≥ 24: aOR, 1.85; 95% CI, 1.14-3.00; high response: aOR, 1.60; 95% CI, 1.02–2.50). Letrozole co-treatment was also associated with decreased risks of gestational diabetes (aOR, 0.34; 95% CI, 0.15–0.69) and small for gestational age (SGA) fetuses (aOR, 0.42; 95% CI, 0.22–0.75) in fresh ET cycles. These finding were robust in both PSM and IPW models. Our findings suggested that letrozole co-treatment in antagonist protocol for IVF/ICSI was associated with a comparable live birth rate following fresh ET. Further prospective randomized studies are needed to verify our results.


  • Open Access

    Impact of 2.5 mg versus 5 mg letrozole co-treatment in an antagonist protocol for IVF: a retrospective study

    by Jing Lin, Fenglu Wu, Kai Zhang, Yanwen Zhu, Bian Wang, Qianqian Zhu, Jiaying Lin

    Objective: The present study aimed to compare the effectiveness of two different doses of letrozole (2.5 mg and 5 mg daily) in an antagonist protocol for infertile women with normal ovarian reserve.Methods: This retrospective cohort study included infertile women who underwent in vitro fertilization treatment with letrozole co-treatment at doses of 2.5 mg and 5 mg from 2007 – 2021 at Shanghai Ninth People’s Hospital (Shanghai, China). The control group comprised infertile women who received gonadotropin-releasing hormone antagonist alone. The primary outcome was the cumulative live birth rate, while secondary outcomes included follicular phase endocrine parameters, ovarian stimulation outcomes, pregnancy outcomes, and the incidences of maternal and neonatal complications. Baseline and follow-up data were compared between the groups using ANOVA for normally distributed variables, the Kruskal-Wallis test for non-normally distributed variables, and the Chi-square test for categorical variables.Results: A total of 422 participants were enrolled in the study, with 211 women in the antagonist group, 109 women in the 2.5 mg letrozole co-treatment group, and 102 women in the 5 mg letrozole co-treatment group. Letrozole co-treatment significantly suppressed oestradiol and follicle-stimulating hormone concentrations from stimulation day 5 and onwards, while increasing luteinizing hormone levels on stimulation day 5 and trigger day. The effect was more pronounced with a 5 mg dose of letrozole compared to a 2.5 mg dose (P < 0.05). Administration of 5 mg letrozole reduced the gonadotropin dose (P < 0.05) without negatively affecting the number of oocytes retrieved and subsequent embryo parameters (P > 0.05). The analysis of cumulative live birth rates showed rates of 29.4% in the letrozole 5 mg group, 27.5% in the letrozole 2.5 mg group, and 33.6% in the control group, with no statistically significant difference (P > 0.05). There were no reported pregnancy complications in the two letrozole groups. Additionally, there were no significant differences among the three groups in terms of gestational age and birth weight for both singleton and twin births.Conclusion: This study indicates that the administration of letrozole in an antagonist protocol, at both 2.5 mg and 5 mg dosages, results in comparable clinical outcomes.


  • COVID‐19 infection after oocyte retrieval did not have detrimental effects on embryo implantation for frozen embryo transfer

    by Haiyan Guo, Mingru Yin, Yali Liu, Bian Wang, Jiaying Lin, Qianqian Zhu

    Patients preparing for their renewal fertility treatments with embryos frozen before coronavirus disease 2019 (COVID‐19) infection do not need to be concerned about the potential impact of COVID‐19 infection on oocyte quality and embryonic development. However, many women are still hesitant to undergo frozen embryo transfer (FET) due to fear of the detrimental effect of COVID‐19 infection on endometrial receptivity and embryo implantation. The objective was to explore whether COVID‐19 infection after oocyte retrieval is related to an increased risk of adverse pregnancy outcomes in a cohort of Chinese women undergoing FET. A retrospective cohort study was conducted among 300 infertile women undergoing FET with embryos frozen before COVID‐19 infection. Women were categorized into noninfection, infection before FET, or infection after FET groups. Multivariable logistic regression was performed to assess the association of COVID‐19 infection with clinical pregnancy outcomes, including biochemical pregnancy, clinical pregnancy, and early miscarriage. The implantation rates for patients in the group with infection before FET (29.14%) and the group with infection after FET (30.38%) were not significantly lower than those in the noninfection group (31.03%). The rate of biochemical pregnancy (54.55% vs. 52.27%, p = 0.750; 43.14% vs. 52.27%, p = 0.209) was not significantly different among the three groups. Although the clinical pregnancy rate showed a declining trend from 45.45% in the noninfection group to 38.27% in the group with infection after FET, this result was not statistically significant. The early miscarriage rate was similar in the group with infection before FET and the group with infection after FET compared with that in the noninfection group (3.64% vs. 5.68%, p = 0.496; 6.86% vs. 5.68%, p = 0.739). After adjusting for potential confounders, the biochemical pregnancy rate, clinical pregnancy rate, and early miscarriage rate were not significantly different for patients with infection before or after FET compared with patients without infection. This research indicated that COVID‐19 infection after oocyte retrieval with embryos frozen before infection did not cause any detrimental effect on endometrial receptivity for embryo implantation.


  • Relationships between birth weight discordance and maternal and perinatal risks among twin pregnancies conceived following frozen embryo transfer

    by Jing Lin, Yanwen Zhu, Bian Wang, Tong Du, Kai Zhang, Qianqian Zhu, Jiaying Lin

    STUDY QUESTION: Is intertwin birth weight discordance associated with adverse maternal and perinatal outcomes following frozen embryo transfer (FET)? SUMMARY ANSWER: For twins conceived following FET, intertwin birth weight discordance is related to elevated risks of neonatal mortality irrespective of chorionicity, and the risk of hypertensive disorders of pregnancy (HDP) is elevated for the mothers of dichorionic twins affected by such birth weight discordance. WHAT IS KNOWN ALREADY: While the relationships between intertwin birth weight discordance and adverse maternal or fetal outcomes have been studied for naturally conceived twins, similarly comprehensive analyses for twins conceived using ART remain to be performed. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study of all twin births from 2007 to 2021 at Shanghai Ninth People’s Hospital in Shanghai, China that were conceived following FET (N = 6265). PARTICIPANTS/MATERIALS, SETTING, METHODS: Intertwin birth weight discordance was defined as a 20% difference in neonatal birth weights. The primary study outcome was the incidence of HDP and neonatal death while secondary outcomes included gestational diabetes, placenta previa, placental abruption, intrahepatic cholestasis of pregnancy, preterm premature rupture of the membranes, Cesarean delivery, gestational age, birth weight, stillbirth, birth defect, neonatal jaundice, necrotizing enterocolitis, and pneumonia incidence. Logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% CIs for maternal and neonatal outcomes. Subgroup analyses were conducted, and Kaplan–Meier survival analysis was used to estimate the survival probability. The sensitivity analysis was performed with a propensity score-based patient-matching model, an inverse probability weighting model, a restricted cubic spline analysis, and logistic regression models using other percentage cutoffs for discordance. MAIN RESULTS AND THE ROLE OF CHANCE: Of 6101 females that gave birth to dichorionic twins during the study interval, birth weight discordance was observed in 797 twin pairs (13.1%). In this cohort, intertwin birth weight discordance was related to an elevated risk of HDP (aOR 1.56; 95% CI 1.21–2.00), and this relationship was confirmed through sensitivity analyses. Hypertensive disease risk rose as the severity of this birth weight discordance increased. Discordant birth weight was also linked to increased odds of neonatal mortality (aOR 2.13; 95% CI 1.03–4.09) and this risk also increased with the severity of discordance. Of the 164 women with monochorionic twins, the discordant group exhibited an elevated risk of neonatal death compared to the concordant group (crude OR 9.00; 95% CI 1.02–79.3). LIMITATIONS, REASONS FOR CAUTION: The limitations of this study are its retrospective nature and the fact that the available data could not specify which twins were affected by adverse outcomes. There is a lack of an established reference birth weight for Chinese twins born at a gestational age of 24–41 weeks. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that twins exhibiting a birth weight discordance are related to an elevated risk of adverse maternal and perinatal outcomes, emphasizing a potential need for higher levels of antenatal surveillance in these at-risk pregnancies. STUDY FUNDING/COMPETING INTEREST(S): Authors declare no conflict of interest. This study was funded by the Clinical Research Program of Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (JYLJ202118) and the National Natural Science Foundation of China (Grant Nos 82271693 and 82273634). TRIAL REGISTRATION NUMBER: N/A.


  • Open Access

    Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment

    by Yali Liu, Jiaying Lin, Xi Shen, Qianqian Zhu, Yanping Kuang

    Background: Women who have polycystic ovary syndrome (PCOS) with high body mass index (BMI) typically have an attenuated ovarian response and decreased follicular size, which are linked to unfavourable clinical outcomes following in vitro fertilization (IVF) therapy. The follicular output rate (FORT), a qualitative indicator of follicular response, seems to be positively linked to the clinical outcomes of IVF. Progestin-primed ovarian stimulation (PPOS) has become an alternative to gonadotropin-releasing hormone (GnRH) analogues to inhibit the premature luteinizing hormone (LH) surge. As letrozole (LE) shows promise in enhancing ovarian response, we compared PPOS with and without LE for PCOS in high BMI women with a focus on the FORT and associated clinical and pregnancy outcomes.Methods: For the recruited 1508 women, ten variables including AFC; age; basal sex hormone level; BMI; infertility type; period of infertility and number of previous IVF attempts were chosen in the propensity score matching (PSM) model to match 1374 women who taken the MPA+ hMG protocol with 134 women who received the MPA+ hMG+ LE treatment at a 1:1 ratio. FORT was selected as the primary outcome measure. The number of oocytes retrieved, viable embryos, hMG dosage, duration, oocyte maturity rate, fertilization rate, and implantation rate were established as secondary outcomes.Results: FORT was substantially elevated in the MPA+hMG+LE group compared with the MPA+hMG group (61% [35%, 86%] vs. 40% [25%, 60%], P <.001). Interestingly, the LE cotreatment group had a considerably lower mature oocyte rate despite having a similar number of mature oocytes and embryos recovered. The average hMG dosages and durations in the study group were similar to those in the control group. The implantation rate in the study group was numerically higher but without statistic significant than that in the control groups (43.15% (107/248) vs. 38.59% (115/298), OR 1.008, 95% CI 0.901-1.127; P >.05).Conclusion: The effect of LE combined with PPOS on FORT is better than the effect of the standard PPOS treatment in women with PCOS and a high BMI, but there is no substantially beneficial impact on pregnancy outcomes or the cycle features of COS, including consumption of hMG.


  • Open Access

    Live birth rate and neonatal outcomes following interventional embolization of hydrosalpinx

    by Haiyan Guo, Tong Du, Qifeng Lyu, Ling Wu, Weiran Chai, Qianqian Zhu

    Background: Hydrosalpinx has a negative effect on the pregnancy outcomes of in vitro fertilization and embryo transfer (IVF-ET), and the pretreatment for hydrosalpinx play an important role in improving the outcomes of IVF-ET. This study aimed to investigate the impacts of interventional embolization of hydrosalpinx on the live birth rate and neonatal outcome after in-vitro fertilization. Method: In the present retrospective study, 3351 women receiving the first frozen embryo transfer (FET) after freeze-all policy were reviewed. Patients who received interventional embolization of hydrosalpinx (n = 1268) were included in the study group and those with hydrosalpinx-free bilateral fallopian tube obstruction (n = 2083) in the control group. The primary outcome was live birth (LB) rate; the secondary endpoints included rates of implantation, clinical pregnancy (CP), multiple pregnancy, and pregnancy loss. Results: The LB rate was similar between embolization group (39.91%) and control group (43.21%) (P > 0.05). The rate of implantation (35.81% vs. 32.24%), CP (50.84% vs. 47%) and multiple pregnancy rate (28.71% vs. 24.16%) in the control group were significantly higher than in the embolization group (P < 0.05). The miscarriage rate (39.91%, vs 43.21%, P > 0.05), ectopic gestation rate (2.35% vs 2.83%, P > 0.05), and ongoing pregnancy rate (41.56% vs 44.89%, P > 0.05) were comparable between two groups. After adjustment for confounding factors, interventional embolization of hydrosalpinx was found to have no influence on the LB rate. The thicker endometrium, more embryos transferred, and transfer of blastocyst stage embryos significantly increased the LB rate and CP rate. Conclusion: The interventional embolization of hydrosalpinx can achieve the LB rate similar to that of hydrosalpinx-free obstruction patients with less risk, less pain and reduced medical cost. Thus, embolization of hydrosalpinx is one of the preferable clinical treatments for patients with hydrosalpinx.


  • Open Access

    The effect of body mass index on neonatal outcomes in Chinese women with polycystic ovary syndrome

    by Haiyan Guo, Bian Wang, Hongyuan Gao, Qianqian Zhu

    Aim: This study aimed to explore the effect of body mass index (BMI) on neonatal outcomes in patients with polycystic ovary syndrome following the frozen embryo transfer (FET).Methods: This study included 1,676 singletons born from mothers with polycystic ovary syndrome (PCOS) after FET between 1 Jan 2007 and 31 Dec 2019. BMI was categorized into three groups: underweight (BMI less than 18.5 kg/m2), normal weight (BMI between 18.5 and 24.9 kg/m2), and overweight (BMI between 25.0 and 29.9 kg/m2). Logistic regression models with generalized estimating equations were used for clustering by patients to explore the effect of BMI on neonatal outcomes.Results: When compared to normal-weight mothers, the rate of large for gestational age (LGA) babies (adjusted odds ratio [aOR] 0.45, 95% confidence interval [95%CI] 0.22–0.93) significantly decreased for underweight mothers and significantly increased (aOR 1.82, 95%CI 1.38–2.41) for overweight mothers. The rate of high birth weight among infants from overweight mothers (aOR 1.75, 95%CI 1.15–2.65) was significantly higher than those from normal-weight mothers after adjusting for known confounding factors. The rate of small for gestational age (SGA) singleton (aOR 2.37, 95%CI 1.14–4.93) was lower among underweight mothers than normal-weight mothers.Conclusion: Maternal underweight was a significant protective factor against LGA infants for singletons born from patients with PCOS after FET, whereas maternal overweight was an adverse factor for LGA infants.